Stock Events

Helix Biomedix 

$23.5
3
+$0+0% Thursday 20:00

Statistics

Day High
24
Day Low
24
52W High
24
52W Low
23
Volume
1
Avg. Volume
3
Mkt Cap
5.28M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

30SepConfirmed
Q4 2010
Q1 2011
Q2 2011
Q3 2011
Q4 2011
Q1 2012
Q2 2012
-4.74
-3.16
-1.58
0
Expected EPS
0
Actual EPS
-4.7376

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HXBM. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of treatments for serious medical conditions, competing in the biopharmaceutical space similar to Helix Biomedix.
AMGEN
AMGN
Mkt Cap177.72B
Amgen Inc. is a biotech firm developing novel therapies in various therapeutic areas, overlapping with Helix Biomedix's focus on innovative biopharmaceutical solutions.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals Incorporated operates in the biotechnology and pharmaceuticals sector, developing drugs that could potentially compete with Helix Biomedix's product offerings.
Biogen
BIIB
Mkt Cap32.96B
Biogen Inc. specializes in discovering and delivering therapies for neurological and neurodegenerative diseases, competing with Helix Biomedix in the biotech innovation sector.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets medicines in areas potentially overlapping with Helix Biomedix's interests.
Incyte
INCY
Mkt Cap14.79B
Incyte Corporation specializes in oncology products but also has a portfolio that could compete with Helix Biomedix in broader biopharmaceutical applications.
Exelixis
EXEL
Mkt Cap6.58B
Exelixis, Inc. is a biotechnology company that develops small molecule therapies for the treatment of cancer, which could intersect with Helix Biomedix's market.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.97B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing in the same innovative treatment space as Helix Biomedix.

About

Biotechnology
Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.
Show more...
CEO
Employees
8
Country
US
ISIN
US4232875074

Listings

OTCM
US
HXBM